594 related articles for article (PubMed ID: 30857514)
1. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
[TBL] [Abstract][Full Text] [Related]
2. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Udy AA; Paul SK; Lipman J; ;
Crit Care Resusc; 2013 Sep; 15(3):179-85. PubMed ID: 23944203
[TBL] [Abstract][Full Text] [Related]
3. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
Dulhunty JM; Brett SJ; De Waele JJ; Rajbhandari D; Billot L; Cotta MO; Davis JS; Finfer S; Hammond NE; Knowles S; Liu X; McGuinness S; Mysore J; Paterson DL; Peake S; Rhodes A; Roberts JA; Roger C; Shirwadkar C; Starr T; Taylor C; Myburgh JA; Lipman J;
JAMA; 2024 Jun; ():. PubMed ID: 38864155
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J;
Am J Respir Crit Care Med; 2015 Dec; 192(11):1298-305. PubMed ID: 26200166
[TBL] [Abstract][Full Text] [Related]
5. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
[TBL] [Abstract][Full Text] [Related]
6. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
[TBL] [Abstract][Full Text] [Related]
7. Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists.
Cotta MO; Dulhunty JM; Roberts JA; Myburgh J; Lipman J
Int J Antimicrob Agents; 2016 Jun; 47(6):436-8. PubMed ID: 27179814
[TBL] [Abstract][Full Text] [Related]
8. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Lipman J
Clin Infect Dis; 2013 Jan; 56(2):236-44. PubMed ID: 23074313
[TBL] [Abstract][Full Text] [Related]
11. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
Udy AA; Dulhunty JM; Roberts JA; Davis JS; Webb SAR; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J; ;
Int J Antimicrob Agents; 2017 May; 49(5):624-630. PubMed ID: 28286115
[TBL] [Abstract][Full Text] [Related]
12. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
[TBL] [Abstract][Full Text] [Related]
14. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
15. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
Monti G; Bradic N; Marzaroli M; Konkayev A; Fominskiy E; Kotani Y; Likhvantsev VV; Momesso E; Nogtev P; Lobreglio R; Redkin I; Toffoletto F; Bruni A; Baiardo Redaelli M; D'Andrea N; Paternoster G; Scandroglio AM; Gallicchio F; Ballestra M; Calabrò MG; Cotoia A; Perone R; Cuffaro R; Montrucchio G; Pota V; Ananiadou S; Lembo R; Musu M; Rauch S; Galbiati C; Pinelli F; Pasin L; Guarracino F; Santarpino G; Agrò FE; Bove T; Corradi F; Forfori F; Longhini F; Cecconi M; Landoni G; Bellomo R; Zangrillo A;
JAMA; 2023 Jul; 330(2):141-151. PubMed ID: 37326473
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE).
Laporte-Amargos J; Gudiol C; Arnan M; Puerta-Alcalde P; Carmona-Torre F; Huguet M; Albasanz-Puig A; Parody R; Garcia-Vidal C; Del Pozo JL; Batlle M; Tebé C; Rigo-Bonnin R; Muñoz C; Padullés A; Tubau F; Videla S; Sureda A; Carratalà J
Trials; 2020 May; 21(1):412. PubMed ID: 32423462
[TBL] [Abstract][Full Text] [Related]
18. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
[TBL] [Abstract][Full Text] [Related]
20. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
